The diagnostics company Quanterix hopes to gain new ground following the FDA’s recent full approval of Eisai and Biogen’s Leqembi treatment for Alzheimer’s disease, with the launch of an ultrasensitive blood test and a refreshed storefront for healthcare providers.

Dubbed Lucent Diagnostics, the company’s outlet will house LucentAD—a test that aims to help clinicians examine patients showing the early cognitive symptoms of the neurodegenerative disease.

LucentAD searches the blood for small traces of the protein p-Tau 181, which can be found in plasma and cerebrospinal fluid, and has been linked to the presence of amyloid plaque build-ups within the brain—allowing for an easier peek into what’s happening inside the body without relying exclusively on a PET scan or a more invasive procedure. ….